K M Akkerhuis

Summary

Affiliation: University Hospital
Country: The Netherlands

Publications

  1. ncbi Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention
    K M Akkerhuis
    Thoraxcenter, University Hospital Rotterdam, H 543, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    JAMA 286:78-82. 2001
  2. ncbi Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?
    K Martijn Akkerhuis
    Thoraxcenter, University Hospital Rotterdam, The Netherlands
    Circulation 105:554-6. 2002
  3. ncbi Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glyco
    K M Akkerhuis
    Thoraxcenter, Erasmus University and University Hospital Rotterdam, Rotterdam, The Netherlands
    J Electrocardiol 33:127-36. 2000
  4. ncbi Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
    E Boersma
    Thoraxcenter, University Hospital Rotterdam, Netherlands
    Circulation 100:2045-8. 1999
  5. ncbi Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators
    E Boersma
    University Hospital Rotterdam, Rotterdam, The Netherlands
    Circulation 101:2557-67. 2000
  6. ncbi Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker
    E Ronner
    University Hospital Rotterdam, Rotterdam, The Netherlands
    Eur Heart J 23:239-46. 2002
  7. ncbi Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients
    K M Akkerhuis
    The Thoraxcenter, University Hospital Rotterdam, Room H-543, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur Heart J 22:1997-2006. 2001
  8. doi Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome
    R M Oemrawsingh
    Thoraxcenter, Department of Cardiology, ErasmusMC and Cardiovascular Research Institute COEUR, Rotterdam, The Netherlands
    Heart 97:1061-6. 2011
  9. doi Prognostic significance of QRS duration in patients with suspected coronary artery disease referred for noninvasive evaluation of myocardial ischemia
    Arend F L Schinkel
    Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Am J Cardiol 104:1490-3. 2009
  10. ncbi Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial
    Marino Labinaz
    University of Ottawa Heart Institute, Ottawa, Ontario
    Can J Cardiol 20:773-8. 2004

Detail Information

Publications11

  1. ncbi Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention
    K M Akkerhuis
    Thoraxcenter, University Hospital Rotterdam, H 543, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    JAMA 286:78-82. 2001
    ..Because of its potent inhibition of platelet aggregation, the effect of abciximab on risk of stroke is a concern...
  2. ncbi Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?
    K Martijn Akkerhuis
    Thoraxcenter, University Hospital Rotterdam, The Netherlands
    Circulation 105:554-6. 2002
    ....
  3. ncbi Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glyco
    K M Akkerhuis
    Thoraxcenter, Erasmus University and University Hospital Rotterdam, Rotterdam, The Netherlands
    J Electrocardiol 33:127-36. 2000
    ..Integration of these systems in coronary care units and emergency wards should, therefore, be recommended...
  4. ncbi Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
    E Boersma
    Thoraxcenter, University Hospital Rotterdam, Netherlands
    Circulation 100:2045-8. 1999
    ..The question arises as to whether these 2 beneficial effects are independent and additive...
  5. ncbi Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators
    E Boersma
    University Hospital Rotterdam, Rotterdam, The Netherlands
    Circulation 101:2557-67. 2000
    ..Appropriate treatment policies should include an accurate estimate of a patient's baseline risk. Risk modeling to date has been underutilized in patients with acute coronary syndromes without persistent ST-segment elevation...
  6. ncbi Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker
    E Ronner
    University Hospital Rotterdam, Rotterdam, The Netherlands
    Eur Heart J 23:239-46. 2002
    ..Four groups were distinguished, who underwent percutaneous coronary intervention on day 1; on days 2 or 3; at 4 to 7 days; or between 8 until 30 days, for eptifibatide- and placebo-treated patients...
  7. ncbi Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients
    K M Akkerhuis
    The Thoraxcenter, University Hospital Rotterdam, Room H-543, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur Heart J 22:1997-2006. 2001
    ..CONCLUSIONS: This analysis emphasizes the need for integration of multilead ECG-ischaemia monitoring systems in coronary care units and emergency wards to improve early risk stratification in patients with acute coronary syndromes...
  8. doi Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome
    R M Oemrawsingh
    Thoraxcenter, Department of Cardiology, ErasmusMC and Cardiovascular Research Institute COEUR, Rotterdam, The Netherlands
    Heart 97:1061-6. 2011
    ....
  9. doi Prognostic significance of QRS duration in patients with suspected coronary artery disease referred for noninvasive evaluation of myocardial ischemia
    Arend F L Schinkel
    Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Am J Cardiol 104:1490-3. 2009
    ..This risk is persistent after adjustment for clinical variables, left ventricular function, and myocardial ischemia...
  10. ncbi Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial
    Marino Labinaz
    University of Ottawa Heart Institute, Ottawa, Ontario
    Can J Cardiol 20:773-8. 2004
    ..For patients with ACS undergoing percutaneous balloon angioplasty without coronary stenting in the era of platelet glycoprotein IIb/IIIa blockade, the long-term prognosis is less clear...
  11. doi Tailor-made therapy for the prevention of acute coronary syndromes: future role of biomarkers in risk stratification and disease management
    Rohit M Oemrawsingh
    Expert Rev Cardiovasc Ther 6:435-7. 2008